Francisco del Caño-Ochoa

Dr. Francisco del Caño-Ochoa

Instituto de Biomedicina de Valencia-CSIC (IBV-CSIC), Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Structure
Verified
Journal Article
Closed access
MMMaría Moreno-Morcillo
María Moreno-Morcillo
AGAraceli Grande-García
Araceli Grande-García
ARAlba Ruiz-Ramos
Alba Ruiz-Ramos
FCFrancisco del Caño-Ochoa
Francisco del Caño-Ochoa
JBJasminka Boskovic
Jasminka Boskovic
SRSantiago Ramon-Maiques
Santiago Ramon-Maiques

22 July 2021 in Protein Science
Verified
Journal Article
Open access
PDF file
FCFrancisco del Caño-Ochoa
Francisco del Caño-Ochoa
SRSantiago Ramon-Maiques
Santiago Ramon-Maiques
CAD is a 1.5 MDa particle formed by hexameric association of a 250 kDa protein divided into different enzymatic domains, each catalyzing one of the initial reactions for de novo biosynthesis of pyrimidine nucleotides: glutaminase‐dependent Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, and Dihydroorotase. The pathway for de novo pyrimidine synthesis is essential for cell proliferation and is conserved in all living organisms, but the covalent linkage of the first enzymatic activities into a multienzymatic CAD particle is unique to animals. In other organisms, these enzymatic activities are encoded as monofunctional proteins for which there is abundant structural and biochemical information. However, the knowledge about CAD is scarce and fragmented. Understanding CAD requires not only to determine the three‐dimensional structures and define the catalytic and regulatory mechanisms of the different enzymatic domains, but also to comprehend how these domains entangle and work in a coordinated and regulated manner. This review summarizes significant progress over the past 10 years toward the characterization of CAD's architecture, function, regulatory mechanisms, and cellular compartmentalization, as well as the recent finding of a new and rare neurometabolic disorder caused by defects in CAD activities.

1 January 2019
Verified
Book Chapter
Closed access
PDF file
FCFrancisco del Caño-Ochoa
Francisco del Caño-Ochoa
MMMaría Moreno-Morcillo
María Moreno-Morcillo
SRSantiago Ramon-Maiques
Santiago Ramon-Maiques

11 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LBLeo Bellin
Leo Bellin
FCFrancisco del Caño-Ochoa
Francisco del Caño-Ochoa
AVAdrian Velazquez-Campoy
Adrian Velazquez-Campoy
TMTorsten Moehlmann
Torsten Moehlmann
SRSantiago Ramon-Maiques
Santiago Ramon-Maiques
Aspartate transcarbamoylase (ATC), an essential enzyme for de novo pyrimidine biosynthesis, is uniquely regulated in plants by feedback inhibition of uridine 5-monophosphate (UMP). Despite its importance in plant growth, the structure of this UMP-controlled ATC and the regulatory mechanism remain unknown. Here, we report the crystal structures of Arabidopsis ATC trimer free and bound to UMP, complexed to a transition-state analog or bearing a mutation that turns the enzyme insensitive to UMP. We found that UMP binds and blocks the ATC active site, directly competing with the binding of the substrates. We also prove that UMP recognition relies on a loop exclusively conserved in plants that is also responsible for the sequential firing of the active sites. In this work, we describe unique regulatory and catalytic properties of plant ATCs that could be exploited to modulate de novo pyrimidine synthesis and plant growth.

26 March 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
HTHsin-Fang Tu
Hsin-Fang Tu
CKChun-Jung Ko
Chun-Jung Ko
CLChing-Tai Lee
Ching-Tai Lee
CLCheng-Fan Lee
Cheng-Fan Lee
SLShao-Wei Lan
Shao-Wei Lan
GCGeen-Dong Chang
Geen-Dong Chang
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced CD8+ T lymphocyte function. Here we show that the EGFR-TKI afatinib suppresses CD8+ T lymphocyte proliferation, and we identify CAD, a key enzyme of de novo pyrimidine biosynthesis, to be a novel afatinib target. Afatinib reduced tumor-infiltrating lymphocyte numbers in Lewis lung carcinoma (LLC)–bearing mice. Early afatinib treatment inhibited CD8+ T lymphocyte proliferation in patients with non–small cell lung cancer, but their proliferation unexpectedly rebounded following long-term treatment. This suggests a transient immunomodulatory effect of afatinib on CD8+ T lymphocytes. Sequential treatment of afatinib with anti-PD1 immunotherapy substantially enhanced therapeutic efficacy in MC38 and LLC-bearing mice, while simultaneous combination therapy showed only marginal improvement over each single treatment. These results suggest that afatinib can suppress CD8+ T lymphocyte proliferation by targeting CAD, proposing a timing window for combined therapy that may prevent the dampening of ICB efficacy by EGFR-TKIs. Significance: This study elucidates a mechanism of afatinib-mediated immunosuppression and provides new insights into treatment timing for combined targeted therapy and immunotherapy.

28 May 2020 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
FCFrancisco del Caño-Ochoa
Francisco del Caño-Ochoa
BNBobby G. Ng
Bobby G. Ng
MAMalak Abedalthagafi
Malak Abedalthagafi
MAMohammed Almannai
Mohammed Almannai
RCRonald D. Cohn
Ronald D. Cohn
SRSantiago Ramon-Maiques
Santiago Ramon-Maiques
Purpose Pathogenic autosomal recessive variants in CAD, encoding the multienzymatic protein initiating pyrimidine de novo biosynthesis, cause a severe inborn metabolic disorder treatable with a dietary supplement of uridine. This condition is difficult to diagnose given the large size of CAD with over 1000 missense variants and the nonspecific clinical presentation. We aimed to develop a reliable and discerning assay to assess the pathogenicity of CAD variants and to select affected individuals that might benefit from uridine therapy. Methods Using CRISPR/Cas9, we generated a human CAD-knockout cell line that requires uridine supplements for survival. Transient transfection of the knockout cells with recombinant CAD restores growth in absence of uridine. This system determines missense variants that inactivate CAD and do not rescue the growth phenotype. Results We identified 25 individuals with biallelic variants in CAD and a phenotype consistent with a CAD deficit. We used the CAD-knockout complementation assay to test a total of 34 variants, identifying 16 as deleterious for CAD activity. Combination of these pathogenic variants confirmed 11 subjects with a CAD deficit, for whom we describe the clinical phenotype. Conclusions We designed a cell-based assay to test the pathogenicity of CAD variants, identifying 11 CAD-deficient individuals who could benefit from uridine therapy.